Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
Doxazosin 4 mg Japanese marketed IR tablet
Doxazosin 4 mg ODT with water
Doxazosin 4 mg ODT without water
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Bioequivalence, Orally-disintegrating Tablet
Eligibility Criteria
Inclusion Criteria:
- Japanese healthy male subjects
Exclusion Criteria:
- Baseline orthostatic hypotension defined as a ≥20 mm Hg reduction in SBP, a ≥10 mm Hg reduction in DBP and/or the development of significant postural symptoms (dizziness, lightheadedness, vertigo) when going from the supine to standing position.
Sites / Locations
- Pfizer Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
A
B
C
Arm Description
Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
Outcomes
Primary Outcome Measures
Peak plasma concentration (Cmax) and AUC from zero to the last sampling point (AUCt) of doxazosin 4 mg Orally Disintegrating Tablet (ODT) without water compared to doxazosin 4 mg Japanese marketed Immediate Release (IR) tablet under fasted conditions
Secondary Outcome Measures
Cmax and AUCt of doxazosin 4 mg ODT with water compared to doxazosin 4 mg Japanese marketed IR tablet under fasted conditions.
Other Pharmacokinetic (PK) parameters (Tmax, AUC from zero to infinity (AUCinf), AUC from zero to the last measurable point (AUClast), elimination rate constant (Kel), t½, and mean residence time (MRT) of doxazosin under all forms of
administration.
Full Information
NCT ID
NCT01389609
First Posted
July 5, 2011
Last Updated
January 26, 2021
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01389609
Brief Title
Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
Official Title
Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
July 2011 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To test bioequivalence of Doxazosin 4 Mg Orally-disintegrating Tablet with Or Without Water to Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Bioequivalence, Orally-disintegrating Tablet
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
Arm Title
B
Arm Type
Experimental
Arm Description
Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
Arm Title
C
Arm Type
Experimental
Arm Description
Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
Intervention Type
Drug
Intervention Name(s)
Doxazosin 4 mg Japanese marketed IR tablet
Intervention Description
Immediate release tablet, 4 mg, single dose
Intervention Type
Drug
Intervention Name(s)
Doxazosin 4 mg ODT with water
Intervention Description
Orally-disintegrating Tablet , 4 mg, single dose with water
Intervention Type
Drug
Intervention Name(s)
Doxazosin 4 mg ODT without water
Intervention Description
Orally-disintegrating Tablet , 4 mg, single dose without water
Primary Outcome Measure Information:
Title
Peak plasma concentration (Cmax) and AUC from zero to the last sampling point (AUCt) of doxazosin 4 mg Orally Disintegrating Tablet (ODT) without water compared to doxazosin 4 mg Japanese marketed Immediate Release (IR) tablet under fasted conditions
Time Frame
up to 48 hours
Secondary Outcome Measure Information:
Title
Cmax and AUCt of doxazosin 4 mg ODT with water compared to doxazosin 4 mg Japanese marketed IR tablet under fasted conditions.
Time Frame
up to 48 hours
Title
Other Pharmacokinetic (PK) parameters (Tmax, AUC from zero to infinity (AUCinf), AUC from zero to the last measurable point (AUClast), elimination rate constant (Kel), t½, and mean residence time (MRT) of doxazosin under all forms of
Time Frame
up to 48 hours
Title
administration.
Time Frame
up to 48 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Japanese healthy male subjects
Exclusion Criteria:
Baseline orthostatic hypotension defined as a ≥20 mm Hg reduction in SBP, a ≥10 mm Hg reduction in DBP and/or the development of significant postural symptoms (dizziness, lightheadedness, vertigo) when going from the supine to standing position.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Shinjuku-ku
State/Province
Tokyo
Country
Japan
12. IPD Sharing Statement
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0351069&StudyName=Bioequivalence%20Study%20of%20Doxazosin%204%20Mg%20Orally-Disintegrating%20Tablet%20With%20Or%20Without%20Water%20To%20Doxazosin%204%20Mg%20Japanese%20Marketed%20Immediate%20
Description
To obtain contact information for a study center near you, click here.
Learn more about this trial
Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
We'll reach out to this number within 24 hrs